Kimball Electronics (KE) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
5 Feb, 2026Executive summary
Q2 sales were $341.3 million, down 5% year-over-year, with strong 15% growth in the medical vertical offset by declines in automotive (down 13%) and industrial segments.
Margins improved versus last year, with gross margin rising to 8.2% from 6.6%, and cash from operations was positive for the eighth consecutive quarter.
The company is rebranding as Kimball Solutions and opened a new medical manufacturing facility in Indianapolis to support its expanded medical strategy.
Net income for the quarter was $3.6 million, with adjusted net income at $6.9 million and adjusted diluted EPS of $0.28.
Restructuring efforts, including the Tampa facility closure, are largely complete, with cumulative costs of $10 million since FY2024.
Financial highlights
Net sales for Q2 were $341.3 million, a 5% decrease year-over-year; foreign exchange had a 2% favorable impact.
Gross margin improved to 8.2% (up 160 bps year-over-year), driven by favorable mix, facility closure, FX, and restructuring.
Adjusted operating income was $15.3 million (4.5% of sales), up from $13.3 million (3.7%) last year.
Adjusted net income was $6.9 million ($0.28/share), compared to $7.4 million ($0.29/share) last year.
Cash and equivalents at quarter-end were $77.9 million; operating cash flow was $6.9 million.
Outlook and guidance
Fiscal 2026 net sales guidance raised to $1.4–$1.46 billion (previously $1.35–$1.45 billion), driven by medical and ramping automotive programs in Europe.
Adjusted operating income now expected at 4.2%–4.5% of net sales, up from prior 4.0%–4.25%.
Capital expenditures guidance unchanged at $50–$60 million for the year.
Management expects to maintain sufficient liquidity for at least the next 12 months, with $363 million in available liquidity.
Effective tax rate for the year expected in the high 20s to low 30s.
Latest events from Kimball Electronics
- Raised FY26 guidance and expanded medical focus drive profitable growth outlook.KE
Company presentation20 Mar 2026 - Medical segment growth and facility expansion drive strategic shift and margin improvement.KE
2026 KeyBanc Capital Markets Healthcare Forum19 Mar 2026 - Q4 sales dropped 13% as inventory and liquidity improved; 2025 outlook remains cautious.KE
Q4 20241 Feb 2026 - Streamlined operations and global focus drive resilience despite EMS market headwinds.KE
The Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - FY 2025 sales expected to decline 8–14% as focus shifts to automation, medical, and debt reduction.KE
2024 Annual Gateway Conference22 Jan 2026 - Q1 sales fell 15% as restructuring, divestitures, and strong cash flow drove debt reduction.KE
Q1 202516 Jan 2026 - Strategic medical CMO expansion and operational discipline set the stage for future growth.KE
The Gateway Conference 20255 Jan 2026 - Q2 FY25 net sales fell 15% year-over-year, but liquidity and balance sheet improved.KE
Q2 202523 Dec 2025 - Annual meeting to vote on directors, auditor, executive pay, and ESG progress amid strong governance.KE
Proxy Filing1 Dec 2025